17:48:49 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-03 Kvartalsrapport 2022-Q1
2022-06-03 Årsstämma 2022
2022-06-03 Ordinarie utdelning OBSRV 0.00 NOK
2022-03-29 Bokslutskommuniké 2021
2022-02-04 Extra Bolagsstämma 2022
2021-11-03 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-16 Extra Bolagsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019


ListaOAX Equities
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo.
2021-09-27 10:00:06
Oslo, September 27th, 2021 - Observe Medical ASA (OSE: OBSRV) continues its
rollout of Sippi®, and today announces that a major regional hospital in Italy
has decided to implement Sippi® in the intensive care unit (ICU), with wireless
connection to the hospital's patient data management system.

"The decision by a major Italian hospital to implement Sippi® in their intensive
care unit, connected wirelessly to the hospital's electronic patient data
management system (PDMS) is important for Observe Medical and our distribution
partner, SIM Italia. The Italian hospital will integrate Sippi® with Digistat®,
a leading PDMS system internationally from Ascom Group. It is an important
reference for us and strengthens the continuous rollout of Sippi® in Italy and
other countries", says Björn Larsson, CEO of Observe Medical ASA.

Sippi® is the only automated digital urine meter with possibility for wireless
data transfer to the hospital patient data management systems and hinders
biofilm formation, that can lead to urinary infections.

Observe Medical is currently executing on the go-to-market strategy for Sippi®
with focus on the clinical rollout in the Nordics and in selected European
countries. Enhanced distribution and market access, gathering of clinical
evidence and experience from pilot users is emphasized in this phase.

"We are excited that the Italian hospital will fully exploit the benefits of
Sippi® in clinical use, through wireless connection to their PDMS system" says
Björn Larsson, and continues:

"As the COVID-19 pandemic situation gradually improves, and with enhanced
customers access for Observe Medical and our distribution partners, this an
important reference for us, further strengthening the current rollout and
commercialization of Sippi®".

For further information, please contact:
Björn Larsson, CEO, mobile: +46 76 620 17 25 E-mail:

About Observe Medical https://observemedical.com/
Observe Medical develops and markets and sells innovative hospital products that
contribute to increased patient safety and a more efficient care system. The
company's ambition is to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in the areas of Urine measurement, Anesthesiology/ICUs and wound care, in
combination with targeted M&A. The company's headquarter is in Oslo, Norway and
its operations is based out of Gothenburg, Sweden. Observe Medical has a direct
sales organization in the Nordics and a distributor network internationally.
Observe Medical's product Sippi® is the only automated digital urine meter with
possibility for wireless data transfer to the hospital patient data management
systems and hinders bacterial migration that can lead to urinary infections
(SippCoat®). Sippi® is CE marked and is currently being launched with focus on
selected markets and hospitals in Nordics and in Europe.